Taxis Pharmaceuticals, Inc.
Publicly observedMonmouth Junction, United States
Seen in a public record (e.g. a government grant database); not otherwise verified.
Details and provenance
| Item | Value | Source | Status |
|---|---|---|---|
| Country | US | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| City / locality | Monmouth Junction | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| Name | Taxis Pharmaceuticals, Inc. | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| UEI (U.S. federal entity ID) | C2NWS2FZS5F5 | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
Recorded events
- Grant12 Aug 2026Publicly observed
NIH SBIR/STTR award: Lead identification of oral FtsZ inhibitors for the treatment of Clostridioides difficile infections(CDI)
USD 294,729.00 · National Institute of Allergy and Infectious Diseases · Source: NIH RePORTER (opens in a new tab)
- Grant16 May 2025Publicly observed
NIH SBIR/STTR award: Lead optimization of oral DHFR inhibitor for the treatment of multidrug-resistant N. gonorrhoeae infections.
USD 1,000,000.00 · National Institute of Allergy and Infectious Diseases · Source: NIH RePORTER (opens in a new tab)
- Grant16 May 2025Publicly observed
NIH SBIR/STTR award: Lead optimization of oral DHFR inhibitor for the treatment of multidrug-resistant N. gonorrhoeae infections.
USD 1,000,000.00 · National Institute of Allergy and Infectious Diseases · Source: NIH RePORTER (opens in a new tab)
- Grant1 May 2024Publicly observed
NIH SBIR/STTR award: Lead optimization of a novel cyclic aryl-indole efflux pump inhibitor (EPI) series in combination with levofloxacin against Pseudomonas aeruginosa
USD 875,798.00 · National Institute of Allergy and Infectious Diseases · Source: NIH RePORTER (opens in a new tab)
- Grant1 May 2024Publicly observed
NIH SBIR/STTR award: Lead optimization of a novel cyclic aryl-indole efflux pump inhibitor (EPI) series in combination with levofloxacin against Pseudomonas aeruginosa
USD 889,610.00 · National Institute of Allergy and Infectious Diseases · Source: NIH RePORTER (opens in a new tab)
Information only — not investment advice or an endorsement. Is this your company? Submit or update its details or request a correction.